AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02341508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg Lpathomab
Study NCT02341508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg Lpathomab
Study NCT02341508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg Lpathomab
Study NCT02341508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 mg/kg Lpathomab
Study NCT02341508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution for intravenous infusion
Study NCT01375270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glucotoxicity
Description: Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
Study NCT01375270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipotoxicity
Description: Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
Study NCT00827541 — intervention group
Intervention type: DRUG
Intervention: Tigecycline
Description: Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
Study NCT02115867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotic
Description: Symprove probiotic
Study NCT02115867 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Symprove probiotic
Study NCT01959425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Off OAT Group (Test)
Description: Discontinuation of OAT Therapy
Study NCT01959425 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: On OAT Group (Control)
Description: Continuation of OAT Therapy
Study NCT05078151 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Whole-Body Diffusion Weighted MRI
Description: MRI at baseline, after four and eight weeks of treatment and at disease progression or treatment discontinuation.
Study NCT03017417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Various exercise tests
Study NCT03017417 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard of care
Description: standard treatment
Study NCT02437656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: J3 - J10 (7 days minimum) : 850 mg 2 times / day~J10 - 48h before surgery : 850 mg 3 times / day
Study NCT02623465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study NCT02623465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro
Description: Administered subcutaneously (SC)
Study NCT02192905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Prevention Program Lifestyle Intervention
Study NCT03870997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Digital Intervention
Description: The Diabetes Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It is tailored to people living with diabetes and highlights the importance of influenza vaccination for this specific patient population.
Study NCT03870997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Generic Digital Intervention
Description: The Generic Digital Intervention is a digital campaign that provides interactive ways (e.g., videos, infographics, quizzes) for individuals to learn about influenza and related complications, and the importance of influenza vaccination. It provides generic influenza vaccination interventions that can be applicable to any adult who should receive influenza vaccination.
Study NCT02046291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
Study NCT02729155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPre
Description: Preconditioning 200 mmHg x 5 minutes before procedure
Study NCT02729155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPost
Description: Postconditioning 200 mmHg x 5 minutes after procedure
Study NCT02729155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Pre
Description: Sham 10 mmHg x 5 minutes before procedure
Study NCT02729155 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Pre
Description: Sham 10 mmHg x 5 minutes before procedure
Study NCT04421222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (QD)
Description: Once daily oral dose of EPI-7386
Study NCT02729155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham-Post
Description: Sham 10 mmHg x 5 minutes after procedure
Study NCT02729155 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Post
Description: Sham 10 mmHg x 5 minutes after procedure
Study NCT01888211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 fatty acid supplementation
Description: 2 grams Omacor daily
Study NCT01888211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 2 grams olive oil daily
Study NCT01683760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Prophylactic fluconazole administration in VLBW infants
Study NCT04626739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19 CAR-T
Description: CD19 CAR-T for CD19 positive R/R non-Hodgkin lymphoma
Study NCT04626739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD22 CAR-T
Description: CD22 CAR-T for CD22 positive R/R non-Hodgkin lymphoma
Study NCT04626739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD19+CD22 CAR-T
Description: CD19+CD22 CAR-T for CD19 positive and CD22 positive R/R non-Hodgkin lymphoma
Study NCT04626739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/㎡ for D-4、D-3 and D-2
Study NCT04626739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/㎡ for D-3 and D-2
Study NCT01718028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Propylene glycol 0.6% ocular emulsion
Study NCT01718028 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium chloride 0.9% saline solution
Study NCT02650219 — intervention group
Intervention type: GENETIC
Intervention: genetic analyses
Study NCT02167763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeraCept Intrauterine Copper Contraceptive
Study NCT02167763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TCu380 IUD
Study NCT02380625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Adults (>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to \<18 yrs): 30mg/kg (oral suspension) daily for 5 days
Study NCT02380625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib and Erlotinib
Description: Sunitinib - Adults (>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to \<18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to \<20kg): 3.5 mg/kg daily for 7 days; Children (>20kg to \<30kg): 3.0 mg/kg daily for 7 days; Children (>30kg to \< 18 yrs): 25 mg/kg daily for 7 days
Study NCT02380625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin and Irbesartan
Description: Atorvastatin - Adults (>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to \<18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to \<18 yrs): 1 x 75mg tablet daily until discharge.
Study NCT02380625 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV fluids and laboratory testing
Description: All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
Study NCT02380625 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: IV fluids and laboratory testing
Description: All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
Study NCT02656810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriparatide
Description: Single subcutaneous injection
Study NCT02428296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
Study NCT03111290 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Cortical Stimulation
Description: A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
Study NCT03111290 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct Cortical Stimulation Sham
Description: Sham trials where no electric pulse is delivered
Study NCT02274454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
Study NCT02274454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
Study NCT03298230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REmotely SuPervised Exercise Training
Description: As described in the Arms section.
Study NCT03298230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Exercise Training
Description: As described in the Arms section.
Study NCT03785574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up
Description: the follow up group would be naturely didived into 2 subgroups depending the hCG regression degree.
Study NCT03785574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
Study NCT03785574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Description: First line treatments：low risk：Methotrexate or ACTD; high risk：EMA-CO
Study NCT00123032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
Study NCT00123032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
Study NCT02015494 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VAX2012Q
Description: Recombinant influenza HA vaccine delivered IM
Study NCT00991341 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell units stored <= 10 days
Description: Pre-storage leukoreduced red blood cell units stored \<=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Study NCT00991341 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell units stored >= 21 days
Description: Pre-storage leukoreduced red blood cell units stored >=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
Study NCT03005509 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TQIM checklist
Description: The intervention phase will include an intense training period covering:~1. Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.~2. Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist.
Study NCT04787406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: Transcranial electrical stimulation device. A weak direct electrical current, up to 2 mA, is passed between two electrodes placed on the scalp. Electrodes are housed in 35 cm2 sponges saturated with 4 ml of saline solution (0.9 % NaCl) per side, per pad.~Stimulation is phased in with a 30 second ramp up period prior to the specified stimulation period and phased-out with a ramp down of the current following the specified stimulation period. For sham stimulation, the ramp-up and ramp-down periods are retained, but stimulation is switched off for during the specified stimulation period.
Study NCT04421222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPI-7386 (BID)
Description: Twice daily oral dose of EPI-7386
Study NCT03420781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo injected twice daily
Study NCT03420781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected twice daily
Study NCT03420781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relamorelin
Description: Relamorelin 10 μg injected twice daily
Study NCT04433364 — intervention group
Intervention type: OTHER
Intervention: biological samples, questionnaires and interviews
Description: Biological samples: to study impact of testing positive for SARS-CoV-2 during pregnancy samples taken in routine clinical care, samples from already existing research biobanks and the newly established COPE biobank will be used. Time-points: inclusion, at delivery mother and fetus. Covid-19 positive group only: 48-96 h, 2 months postpartum for mother and fetus.~Questionnaires: Women and partners in both groups will fill out electronical questionnaires at different time points during pregnancy and until 12 months postpartum based on validated instruments to test for differences in Self-Efficacy, Anxiety and Depression, Health-related quality of life, Sense of Coherence, PTSD Symptoms, Postpartum Bonding, Childbirth experiences and Self-Efficacy of Breastfeeding. The child's health will be assessed regarding infection until 6 weeks of age and development until 4 years.~Interviews: 24-40 women and partners in both groups. Interviews will be conducted 3 to 6 months after childbirth.
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine (Oral Antidepressant)
Description: Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram (Oral antidepressant)
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram (Oral antidepressant)
Description: Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline (Oral Antidepressant)
Description: Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
Study NCT02417064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine Extended Release (XR) (Oral Antidepressant)
Description: Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
Study NCT02264184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Study NCT02264184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Study NCT02264184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paroxetine
Study NCT03170011 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise using the Biodex Sit2Stand Trainer
Description: Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
Study NCT03536910 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Copeptin
Description: Level of copeptin in maternal blood and umbilical cord blood
Study NCT02139098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
Study NCT02139098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: 50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
Study NCT02139098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 5 mg capsule zolpidem before going to bed on 8 out of 17 nights
Study NCT02139098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: 5 mg capsule zolpidem before going to bed on 8 out of 17 nights
Study NCT02139098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
Study NCT02139098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT02920697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S 55746
Description: S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.